The HORMAD1 Knockout HEK293T Polyclonal Cells product is a CRISPR/Cas9-edited cell population with targeted disruption of the HORMAD1 gene. Supplied as live polyclonal knockout cells, this pool contains a heterogeneous mix of edited alleles, avoiding single-cell cloning and enabling rapid deployment in functional studies. The CRISPR-based gene disruption generates a loss-of-function model suitable for investigating HORMAD1-dependent cellular processes in a somatic cell context.
HEK293T cells are a human embryonic kidney epithelial cell line stably expressing SV40 large T antigen, conferring high transfection efficiency and supporting episomal plasmid replication. These cells are a staple in molecular and cell biology for heterologous expression, lentivirus production, and genome editing. Their robust growth and epithelial character make them ideal for biochemical, cell cycle, and DNA damage response assays.
HORMAD1 is a meiosis-specific HORMA domain protein essential for synaptonemal complex assembly and homologous recombination during gametogenesis. It directly interacts with SYCP2 and SYCP3 and coordinates meiotic recombinases DMC1 and RAD51. HORMAD1 expression is transcriptionally controlled by MYBL1 and induced by DNA damage signaling. Ectopic expression in cancers classifies it as a cancer-testis antigen implicated in genomic instability. In somatic cells, HORMAD1 also participates in DNA damage checkpoint responses, potentially through interactions with the ATR?CCHEK1 axis.
Ablation of HORMAD1 in HEK293T eliminates its mitotic DNA damage response functions without meiotic complexity, yielding a clean model to dissect its role in repair and genomic maintenance. The polyclonal knockout population mirrors heterogeneous gene disruption, valuable for studying variable effects or pooled screening. This system enables focused analysis of HORMAD1 involvement in ATR?CCHEK1 signaling and RAD51-mediated homologous recombination repair in a transformed epithelial background relevant to its oncogenic activity.
This tool supports cancer biology research, DNA repair studies, and drug target validation. Applications include Western blot verification of HORMAD1 loss, SYCP3 immunofluorescence, cell cycle analysis, and DNA damage foci assays. The polyclonal pool is also suited for CRISPR rescue experiments. Researchers investigating meiotic gene function in a somatic framework will find this model particularly enabling. For technical support or custom inquiries, contact Ascent Research.
